Literature DB >> 1847647

The prevention of cisplatin-induced renal dysfunction by hydroxyl-containing dithiocarbamates.

L V Reznik1, E M Myazina, E I Shakchmatova, S P Gambaryan, V K Brovtsyn, Y V Natochin, M M Jones.   

Abstract

Two hydroxyl containing dithiocarbamates, sodium N-methyl-D-glucamine dithiocarbamate (NaG) and sodium dihydroxyethyl dithiocarbamate (NaY) have been examined as agents for the control of the renal dysfunction in rats given cisplatin. Of these, NaG was found to be the more effective in controlling such renal dysfunction when administered at 1 and 3 h after 5 mg cisplatin kg-1, i.p. Renal function was examined 5 days after the administration of cisplatin by measurement of serum and urinary levels of creatinine and urea, creatinine clearance, serum and urinary levels of Na+, K+, Mg2+, Ca2+, as well as the concentrations of these ions in the renal medulla and cortex. Treatment of rats given cisplatin with NaG at 1 and 3 h post cisplatin resulted in indices of renal function which were not significantly different from those of animals which had received no cisplatin. The sole difference was found to be a slight increase in renal cortical Na+ concentration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847647      PMCID: PMC1971790          DOI: 10.1038/bjc.1991.55

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Correlation between the toxicity of platinum drugs to L1210 leukaemia cells and their mutagenic properties.

Authors:  P Lecointe; J P Macquet; J L Butour
Journal:  Biochem Biophys Res Commun       Date:  1979-09-12       Impact factor: 3.575

2.  L-methionine suppresses pathological sequelae of cis-platinum in the rat.

Authors:  M A Basinger; M M Jones; M A Holscher
Journal:  Fundam Appl Toxicol       Date:  1990-04

3.  Cisplatin: nephrotoxic action in vertebrates and its prevention.

Authors:  L V Reznik; V T Bakhteeva; E M Myazina; V K Brovtsyn
Journal:  Comp Biochem Physiol C       Date:  1989

4.  [Neutron activation analysis in the pharmacokinetics of cis-dichlorodiammineplatinum (experimental studies)].

Authors:  G A Zedgenidze; V K Brovtsyn; L F Romanova; A B Syrkin; I D Treshchalin
Journal:  Med Radiol (Mosk)       Date:  1980-09

5.  Circadian time dependence of murine tolerance for carboplatin.

Authors:  N A Boughattas; F Lévi; B Hecquet; G Lemaigre; A Roulon; C Fournier; A Reinberg
Journal:  Toxicol Appl Pharmacol       Date:  1988-11       Impact factor: 4.219

6.  Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin.

Authors:  R Qazi; A Y Chang; R F Borch; T Montine; P Dedon; J Loughner; J M Bennett
Journal:  J Natl Cancer Inst       Date:  1988-11-16       Impact factor: 13.506

7.  Sodium N-methyl-D-glucamine dithiocarbamate and cadmium intoxication.

Authors:  L A Shinobu; S G Jones; M M Jones
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1984-03

8.  Mobilization of aged cadmium deposits by dithiocarbamates.

Authors:  L A Shinobu; S G Jones; M M Jones
Journal:  Arch Toxicol       Date:  1983-11       Impact factor: 5.153

9.  Uptake and metabolism of cisplatin by rat kidney.

Authors:  R Safirstein; P Miller; J B Guttenplan
Journal:  Kidney Int       Date:  1984-05       Impact factor: 10.612

10.  Inhibition of cis-diamminedichloroplatinum (II)--induced renal toxicity in the rat.

Authors:  M M Jones; M A Basinger; W M Mitchell; C A Bradley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more
  2 in total

Review 1.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  The relative nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of cisplatin in the rat.

Authors:  M M Jones; M A Basinger; J A Beaty; M A Holscher
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.